x.com/i/article/2036…

This is the moment Oren Hershkovitz, CEO of Enlivex, announced $1.23 Billion in net profit for 2025. Watch the clip below. $ENLV

A significant week for Enlivex. 2025 net income: $1.23B. Diluted EPS: $25.48. Treasury and treasury-related derivative assets: $2.31B. FDA Phase 2b clearance for Allocetra in age-related primary knee osteoarthritis. Four coordinated strategic actions extending the treasury

Most companies fit a category. Enlivex built one. In this clip from our 2025 Earnings Call, Executive Chairman Shai Novik outlines the company's architecture: a clinical strategy advancing quality longevity therapeutics, and a treasury strategy anchored in the economics of